Emerging Diabetes Drugs

Summary

Product description

The Competitive Intelligence Report Emerging Diabetes Drugs & Targets as of November 2008 provides a competitor analysis in the development pipeline of novel emerging antidiabetic treatment modalities for type 1 and 2 diabetes beyond the established targets PPAR agonists, DPP-IV inhibitors, GLP-1 receptor agonists and SGLT inhibitors. The report also includes the diabetes R&D portfolios of those companies with emerging diabetes drugs (incl. R&D projects for established targets).

Emerging diabetes treatment modalities were assigned to four different clusters:

• Metabolic Approaches
• Pancreatic Islet Cell Approaches
• Cell Therapy
• Anti-Inflammatory Approaches

The majority of emerging diabetes drugs still is derived from metabolic approaches:

• Protein Tyrosine Phosphatase 1B (PTP-1B) Inhibitors I
• Glucokinase Activators
• 11-beta Hydroxysteroid Dehydrogenase type-1 (HSD-1) Inhibitors I
• Adenosine 5' monophosphate (AMP)-activated Protein Kinase (AMPK) Activators I
• Glucagon Receptor Agonists & Antagonists
• Glucocorticoid Receptor Agonists & Antagonists
• Glucose-Dependent Insulinotropic Receptor (GDIR) Activators I
• Ghrelin Receptor Antagonists
• FGF-21 Approaches
• Inhibitors of Gluconeogenese
• Various Gluco-Metabolic Approaches -I
• Various Lipo-Metabolic Approaches
• Repositioning Approaches

A rising number of new approaches is directed at the pancreatic islet cell mass and function:

• SIRT
• Gastrin-based Approaches for beta Cell Regeneration
• Preservation of beta Cell Capacity to Produce Insulin
• Vaccines to Prevent Destruction of beta Cells
• Antibodies to Prevent Destruction of beta Cells

The report describes commercial R&D activites in cell therapy of islet cell transplantation and provides information on anti-inflammatory approaches including interleukin-1 (IL-1) directed therapies.

The Competitor Analysis Emerging Diabetes Drugs & Targets also provides the Diabetes Drug R&D pipelines of major players from Big Pharma and specialty biotech companies.

The report includes a compilation of current active projects in research and development of emerging diabetes drugs. Competitor projects are listed in a tabular format providing Information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product category,
• Indication,
• R&D Stage and
• Additional comments with a hyperlink leading to the source of information.

Contents

• Index
• Metabolic Approaches:
  • Protein Tyrosine Phosphatase 1B (PTP-1B) Inhibitors I
  • Glucokinase Activators
  • 11-beta Hydroxysteroid Dehydrogenase type-1 (HSD-1) Inhibitors I
  • Adenosine 5' monophosphate (AMP)-activated Protein Kinase (AMPK) Activators I
  • Glucagon Receptor Agonists & Antagonists
  • Glucocorticoid Receptor Agonists & Antagonists
  • Glucose-Dependent Insulinotropic Receptor (GDIR) Activators I
  • Ghrelin Receptor Antagonists
  • FGF-21 Approaches
  • Inhibitors of Gluconeogenese
  • Various Gluco-Metabolic Approaches -I
  • Various Lipo-Metabolic Approaches
  • Repositioning Approaches
• Pancreatic Islet Cell Approaches:
  • SIRT
  • Gastrin-based Approaches for beta Cell Regeneration
  • Preservation of beta Cell Capacity to Produce Insulin
  • Vaccines to Prevent Destruction of beta Cells
  • Antibodies to Prevent Destruction of beta Cells
• Cell Therapy Approach:
  • Pancreatic Islet Cell Therapies
• Anti-Inflammatory Approaches:
  • Interleukin-1 (IL-1/R) Antagonists
  • Other Anti-Inflammatory Approachres
• Corporate Diabetes R&D Pipelines:
  • 7TM Pharma
  • Aeterna Zentaris
  • Ajinomoto
  • AdiStem
  • Akesis Pharmaceuticals
  • Alba Therapeutics
  • Alize Pharma
  • Amgen
  • Andromeda
  • Apitope
  • Arena Pharmaceuticals
  • Array BioPharma
  • Astellas Pharma
  • AstraZeneca
  • Atherogenics
  • Bayhill Therapeutics
  • Betagenon
  • Bellus Health
  • Biovitrum
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Ceptyr
  • Chemocentryx
  • Crystal Genomics
  • Daiichi Sankyo
  • Dainippon Sumitomo Pharma
  • Develogen
  • Diakine Therapeutics
  • Diamedica
  • Diamyd Medical
  • DiObex
  • Dr. Reddys
  • Eli Lilly
  • Elixir Pharmaceuticals
  • Ensemble Discovery
  • Genaera
  • Geron
  • GlaxoSmithKline
  • HanAll Pharmaceutical
  • Incyte
  • Isis Pharmaceuticals
  • Japan Tobacco
  • Johnson & Johnson
  • Karo Bio
  • Kissei Pharmaceutical Co.
  • Kyorin Pharmaceutical Co.
  • Living Cell Technologies
  • Macrogenics
  • Merck & Co.
  • Mercury Therapeutics
  • Metabasis Therapeutics
  • Metabolex
  • MicroIslet
  • Mitsubishi Tanabe Pharma
  • Neurocrine Biosciences
  • Nicholas Piramal
  • Novartis
  • Novo Nordisk
  • Novocell
  • OSI Pharmaceuticals
  • Osiris Therapeutics
  • Pfizer
  • Proxima Concepts (Diabetology Ltd.)
  • Roche
  • Sanofi-Aventis
  • Sigma-Tau
  • Takeda Pharmaceutical Co.
  • Transition Therapeutics
  • TransTech Pharma
  • Wyeth
  • XOMA
  • Yuhan